Patents by Inventor Melanie S. Horton

Melanie S. Horton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccines against clostridium difficile comprising recombinant toxins
    Patent number: 9388394
    Abstract: The present invention relates to recombinant C. difficile toxin A (TcdA) and toxin B (TcdB) and binary toxin A (CDTa) proteins comprising specifically defined mutations relative to the native toxin sequence that substantially reduce or eliminate toxicity. The invention also relates to vaccines and immunogenic compositions comprising these recombinant toxins, as well as combinations of these toxins with binary toxin B (CDTb), which are capable of providing protection against C. difficile infection and/or the effects thereof. The invention also relates to methods of inducing an immune response to C. difficile comprising administering the vaccines and immunogenic compositions described herein to a patient. The invention also encompasses methods of expressing recombinant C. difficile toxin A and toxin B and CDTa mutants and CDTb in recombinant expression systems.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: July 12, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jon Henry Heinrichs, Jean-Luc Bodmer, Susan Lynn Secore, Aaron Rudy Goerke, Ivette Caro-Aguilar, Melanie S. Horton, Matthew Ryan Miezeiewski, Julie M. Skinner, Su Wang, Jinfu Xie, Rachel Flora Xoconostle, Julie K. Zorman
  • VACCINES AGAINST CLOSTRIDIUM DIFFICILE COMPRISING RECOMBINANT TOXINS
    Publication number: 20150044250
    Abstract: The present invention relates to recombinant C. difficile toxin A (TcdA) and toxin B (TcdB) and binary toxin A (CDTa) proteins comprising specifically defined mutations relative to the native toxin sequence that substantially reduce or eliminate toxicity. The invention also relates to vaccines and immunogenic compositions comprising these recombinant toxins, as well as combinations of these toxins with binary toxin B (CDTb), which are capable of providing protection against C. difficile infection and/or the effects thereof. The invention also relates to methods of inducing an immune response to C. difficile comprising administering the vaccines and immunogenic compositions described herein to a patient. The invention also encompasses methods of expressing recombinant C. difficile toxin A and toxin B and CDTa mutants and CDTb in recombinant expression systems.
    Type: Application
    Filed: January 25, 2013
    Publication date: February 12, 2015
    Applicants: Intervet Inc., Merck Sharp & Dohme Corp.
    Inventors: Jon Henry Heinrichs, Jean-Luc Bodmer, Susan Lynn Secore, Aaron Rudy Goerke, Ivette Caro-Aguilar, Marie-Pierre Gentile, Melanie S. Horton, Matthew Ryan Miezeiewski, Julie M. Skinner, Paulus Jacobus Antonius Sondermeijer, Shyamsundar Subramanian, Karin Huberdina Antonia van der Heijden-Liefkens, Su Wang, Jinfu Xie, Rachel Flora Xoconostle, Julie K. Zorman